HOME >> BIOLOGY >> NEWS
Enzyme inhibitors block replication of SARS virus

ve been looking at other Liponavir-related compounds for similar blocking effects. During these experiments, they found that a group of catalyzing agents used to help promote chemical reactions in the laboratory were actually more powerful in blocking the SARS protease than either the Lopinavir or any of the target compounds.

These organic compounds are called benzotriazole esters. The esters entered the SARS protease site, formed an intermediary compound, then inactivated the SARS enzyme. The findings were confirmed using mass spectrometry analysis of the enzyme intermediary.

"These benzotriazole esters are relatively stable and act as suicide inhibitors," Wong said. "They block the enzyme, are transformed through a co-valent bond, and are unable to get out."

Wong said the findings published today provide better insight into the mode of action of the enzyme, which may lead to development of a drug against SARS. The findings were made by using rapid drug discovery techniques developed in the Wong lab to screen large numbers of weak enzyme inhibitors, and then attaching additional compounds to look for stronger reactions.

Research Associate Chung-Yi Wu, a member of the Wong lab, is the paper's lead author. He said the finding was unexpected.

"We wanted to improve Liponavir activity," Wu said. "But we found this very surprising and serendipitous result."


'"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
28-Mar-2006


Page: 1 2

Related biology news :

1. Enzyme discovery sheds light on vitamin D
2. Enzyme delivered in smaller package protects cells from radiation damage
3. Enzyme Engineering XIX
4. Enzyme inhibitor produces stable disease in patients with advanced solid cell cancers
5. Enzyme shreds Alzheimers protein
6. Enzyme defect leads to hyperinsulinism
7. Eat less, weigh more? Enzyme makes lean mice susceptible to dietary fat
8. Enzyme crystal structure reveals unexpected genome repair functions
9. Enzyme may be target for new anti-inflammatory compounds
10. Enzyme action creates protein linked to Alzheimers disease
11. Enzyme deficiency may contribute to liver cancer, Mount Sinai research indicates

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/12/2017)...  New research undertaken by Fit Small Business ... participants were simply asked which office technology had they not ... standard issue.  Insights on what will be key ... futurists and industry leaders including Penelope Trunk , ... Some of these findings included; ...
(Date:1/11/2017)... Johnson, co-founder of Visikol Inc. a company originally funded with an ... the elite "Forbes 30 Under 30" list in the Science category. ... fields nationwide to be recognized as a leader in business and ... ... PhD candidate at Rutgers University. Visikol , ...
(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., ... iris scanning technology for automotive at CESĀ® 2017. Delta ... GNTX ) to demonstrate the use of iris scanning ... and authenticate the driver in a car, and as ... the driving experience. Delta ID and Gentex ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... San Diego, CA (PRWEB) , ... January 24, ... ... pioneering the development of label-free graphene biosensor assays for fragment-based screening, ... 1317 at the 2017 Society for Laboratory Automation and Screening (SLAS) conference in ...
(Date:1/24/2017)... ... 2017 , ... Edward Buckler, Ph.D., a research geneticist focused ... of Sciences Prize in Food and Agriculture Sciences. He is being honored for ... of Sciences (NAS) Prize in Food and Agriculture Sciences was established in 2016 ...
(Date:1/24/2017)... , Jan. 23, 2017  Today, the Fisher ... they have funded an important study that could lead ... the onset of Alzheimer,s disease. This groundbreaking research was ... University, led by Nobel Laureate Dr. Paul Greengard ... Alzheimer,s disease. Fisher Center scientists have linked ...
(Date:1/23/2017)... Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today ... based Phase 1 trial with severe kidney ... reducing inflamed protein biomarkers in patients with severe kidney ... this is the first time in medical history that ... between epigenetic regulation and its potential for positive disease ...
Breaking Biology Technology:
Cached News: